Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Allison Bratzel maintains a Neutral rating on Travere Therapeutics (NASDAQ:TVTX) and raises the price target from $11 to $12.
August 02, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Travere Therapeutics and raises the price target from $11 to $12.
The raised price target from $11 to $12 indicates a positive outlook, which could lead to a slight increase in investor confidence and a potential short-term price uptick. However, the Neutral rating suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100